AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 322835 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (cytosine arabinoside and 6-thioguanine administered every 12 hours for 5 days with 5-7 days rest intervals)
Number of subjects: 147
Study 322835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (A and B)
Number of subjects: 147
Study 30700130 — intervention group
Group type: EXPERIMENTAL
Intervention: AB023
Number of subjects: 21
Study 30700130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 28295268 — intervention group
Group type: EXPERIMENTAL
Intervention: House-to-house education on cervical cancer and breast cancer prevention
Number of subjects: 1327
Study 25853744 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical ablation
Number of subjects: 260
Study 25853744 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary-vein isolation
Number of subjects: 260
Study 25853744 — intervention group
Group type: COMPARATOR
Intervention: Biatrial maze procedure
Number of subjects: 260
Study 25853744 — intervention group
Group type: COMPARATOR
Intervention: No ablation
Number of subjects: 260
Study 24655865 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic Inguinal Hernia Matrix (IHM; Cook Medical)
Number of subjects: 100
Study 24655865 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene (PP) mesh
Number of subjects: 100
Study 22978733 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision-first (IF) technique
Number of subjects: 180
Study 22978733 — intervention group
Group type: COMPARATOR
Intervention: Needle-first (NF) technique
Number of subjects: 180
Study 19276981 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercises
Number of subjects: 48
Study 19276981 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercises
Number of subjects: 48
Study 19276981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (water-based and land-based exercises)
Number of subjects: 48
Study 17434608 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol x kg(‐1) min(‐1))
Number of subjects: 14
Study 17434608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15257184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nt-proBNP
Number of subjects: 183
Study 15257184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nt-proANP
Number of subjects: 183
Study 15257184 — intervention group
Group type: EXPERIMENTAL
Intervention: Nt-proBNP above median value (21.8 pmol/ml)
Number of subjects: 183
Study 11440917 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women (n = 12)
Number of subjects: 12
Study 11440917 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS women (n = 14)
Number of subjects: 12
Study 11440917 — intervention group
Group type: COMPARATOR
Intervention: Control women (n = 8)
Number of subjects: 12
Study 11440917 — intervention group
Group type: COMPARATOR
Intervention: Control women (n = 12)
Number of subjects: 12
Study 9814456 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in primary symptomatic HPT (n = 52)
Number of subjects: 128
Study 9814456 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in HPT associated with hemodialysis (n = 19)
Number of subjects: 128
Study 9814456 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in HPT associated with renal transplant (n = 15)
Number of subjects: 128
Study 9814456 — intervention group
Group type: COMPARATOR
Intervention: Conservative management in primary asymptomatic HPT (n = 21)
Number of subjects: 128
Study 8032581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone 2.5 g
Number of subjects: 260
Study 8032581 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg
Number of subjects: 260
Study 8032581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 2507481 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutrition (normal diet followed by supplemental liquid formula diet)
Number of subjects: 99
Study 2507481 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition via PEG (percutaneous endoscopically controlled gastrostomy)
Number of subjects: 99
Study 2507481 — intervention group
Group type: COMPARATOR
Intervention: Quality of life index measurement
Number of subjects: 99
Study 2507481 — intervention group
Group type: COMPARATOR
Intervention: Objective parameters of nutrition
Number of subjects: 99
Study 2507481 — intervention group
Group type: COMPARATOR
Intervention: Subjective condition post-DXRT
Number of subjects: 99
Study 31557056 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4614
Study 31557056 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 4614
Study 28759317 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person point of view
Number of subjects: 489
Study 28759317 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive role model
Number of subjects: 489
Study 28759317 — intervention group
Group type: EXPERIMENTAL
Intervention: First-person point of view with positive role model
Number of subjects: 489
Study 28759317 — intervention group
Group type: COMPARATOR
Intervention: Protagonist-reader demographic similarity
Number of subjects: 489
Study 26447745 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 35
Study 26447745 — intervention group
Group type: COMPARATOR
Intervention: Non-preferred music
Number of subjects: 35
Study 26447745 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 35
Study 24621836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 20
Study 24621836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21507262 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour (via prostaglandins, Foley catheter or oxytocin)
Number of subjects: 1760
Study 21507262 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (spontaneous delivery)
Number of subjects: 1760
Study 17920202 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnion
Number of subjects: 102
Study 17920202 — intervention group
Group type: COMPARATOR
Intervention: Topical antimicrobials
Number of subjects: 102
Study 16502422 — intervention group
Group type: EXPERIMENTAL
Intervention: LIM MUCS
Number of subjects: 28
Study 16502422 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS MUCS
Number of subjects: 28
Study 16502422 — intervention group
Group type: EXPERIMENTAL
Intervention: D4S MUCS
Number of subjects: 28
Study 16502422 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall MUCSs
Number of subjects: 28
Study 14689459 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory intervention (auditory, tactile, visual stimulation) for 15 min, twice a day, 5 days a week, for 4 weeks
Number of subjects: 58
Study 14689459 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine orphanage care only)
Number of subjects: 58
Study 11122889 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 0
Study 11122889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification of postremission therapy (multiple courses of high-dose chemotherapy and/or myeloablative therapy)
Number of subjects: 0
Study 11122889 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+7 chemotherapy regimen (3 days of anthracyclines and 7 days of cytarabine)
Number of subjects: 0
Study 11122889 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-tailored therapy
Number of subjects: 0
Study 9078595 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketanserin (n = 69)
Number of subjects: 140
Study 9078595 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) (n = 71)
Number of subjects: 140
Study 9078595 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketanserin
Number of subjects: 140
Study 9078595 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 140
Study 8002148 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitfield's cream
Number of subjects: 153
Study 8002148 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole cream
Number of subjects: 153
Study 3240634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-week program of submaximal aerobic exercise three times weekly
Number of subjects: 55
Study 3240634 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 55
Study 31621251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints (C1)
Number of subjects: 90
Study 31621251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture based on zangfu differentiation (C2)
Number of subjects: 90
Study 31621251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints and based on zangfu differentiation (C3)
Number of subjects: 90
Study 31621251 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter balloon dilation combined with acupuncture (D)
Number of subjects: 90
Study 31621251 — intervention group
Group type: COMPARATOR
Intervention: Catheter balloon dilation (B)
Number of subjects: 90
Study 31621251 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (A)
Number of subjects: 90
Study 28192781 — intervention group
Group type: EXPERIMENTAL
Intervention: Receptive live music
Number of subjects: 70
Study 28192781 — intervention group
Group type: COMPARATOR
Intervention: Verbal relaxation exercise
Number of subjects: 70
Study 25209975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic psychosocial intervention
Number of subjects: 39
Study 25209975 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 39
Study 23305349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic compression boots with 40 mmHg at the heels and 30 mmHg for the legs
Number of subjects: 20
Study 23305349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no compression)
Number of subjects: 20
Study 23305349 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression group
Number of subjects: 20
Study 21512498 — intervention group
Group type: EXPERIMENTAL
Intervention: Neyromidin (15 mg intramuscularly 1 time a day for 10 days)
Number of subjects: 50
Study 21512498 — intervention group
Group type: COMPARATOR
Intervention: Cerebrolysin (10 ml intravenously 1 time a day for 10 days)
Number of subjects: 50
Study 18312058 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (600 mg/day)
Number of subjects: 115
Study 18312058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 16162678 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐UBT 25 mg
Number of subjects: 300
Study 16162678 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐UBT 15 mg
Number of subjects: 300
Study 16162678 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐UBT 10 mg
Number of subjects: 300
Study 16162678 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C‐UBT 15 mg (post-treatment)
Number of subjects: 300
Study 12783624 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused follow-up
Number of subjects: 228
Study 12783624 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 228
Study 10865273 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 30 broad-spectrum sunscreen applied to exposed sites when the child was expected to be in the sun for 30 minutes or more (n=222)
Number of subjects: 309
Study 10865273 — intervention group
Group type: COMPARATOR
Intervention: No sunscreen and no advice about sunscreen use (Control group, n=236)
Number of subjects: 309
Study 9355903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidisomide 200 mg BID
Number of subjects: 1414
Study 9355903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidisomide 400 mg BID
Number of subjects: 1414
Study 9355903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidisomide 600 mg BID
Number of subjects: 1414
Study 9355903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1414
Study 9355903 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidisomide (higher doses)
Number of subjects: 1414
Study 8473088 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG plus antibiotic prophylaxis (cefoxitin: 2 g one hour prior to, followed by 2 g at the end of operation plus 2 g every six hours for 24 hours)
Number of subjects: 159
Study 8473088 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG alone
Number of subjects: 159
Study 8473088 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis (cefoxitin)
Number of subjects: 159
Study 8473088 — intervention group
Group type: COMPARATOR
Intervention: Control (no IVIG)
Number of subjects: 159
Study 2894980 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg twice daily
Number of subjects: 128
Study 2894980 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg twice daily
Number of subjects: 128
Study 2894980 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg twice daily
Number of subjects: 128
Study 2894980 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo twice daily
Number of subjects: 128
Study 29747611 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated surgical crown lengthening with 1.0 mm buccal ferrule (Group CL/F1)
Number of subjects: 40
Study 29747611 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated surgical crown lengthening with 2.0 mm buccal ferrule (Group CL/F2)
Number of subjects: 40
Study 29747611 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated orthodontic forced eruption with 1.0 mm buccal ferrule (Group OE/F1)
Number of subjects: 40
Study 29747611 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated orthodontic forced eruption with 2.0 mm buccal ferrule (Group OE/F2)
Number of subjects: 40
Study 29747611 — intervention group
Group type: COMPARATOR
Intervention: Control group with incomplete ferrule preparation (Group F0)
Number of subjects: 40
Study 27739166 — intervention group
Group type: EXPERIMENTAL
Intervention: FACES instrument
Number of subjects: 197
Study 27739166 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 197
Study 26320403 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight increase (1 kg)
Number of subjects: 4428
Study 26320403 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight
Number of subjects: 4428
Study 23855171 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 60
Study 23855171 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 60
Study 20467146 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy device with defibrillator (CRT-D)
Number of subjects: 0
Study 20467146 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardiac defibrillator (ICD) device
Number of subjects: 0
Study 18026864 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Telemetry Monitors (ETM)
Number of subjects: 51
Study 18026864 — intervention group
Group type: COMPARATOR
Intervention: No Exercise Telemetry Monitors (NETM)
Number of subjects: 51
Study 16177521 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis using detrended fluctuation analysis (DFA)
Number of subjects: 0
Study 12842671 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract extraction in patients with pseudoexfoliation syndrome (PEX)
Number of subjects: 724
Study 12842671 — intervention group
Group type: COMPARATOR
Intervention: Cataract extraction in patients without pseudoexfoliation syndrome (non-PEX)
Number of subjects: 724
Study 10388462 — intervention group
Group type: EXPERIMENTAL
Intervention: Telo Cypro (pure copper wire sheet used as bedsheet)
Number of subjects: 40
Study 10388462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8694041 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone, beta 2‐adrenergic receptor agonist, and an oral corticosteroid taper
Number of subjects: 84
Study 8694041 — intervention group
Group type: COMPARATOR
Intervention: Intravenous aminophylline and inhaled beta 2‐adrenergic receptor agonist
Number of subjects: 84
Study 8694041 — intervention group
Group type: COMPARATOR
Intervention: Beta 2‐adrenergic receptor agonist and corticosteroid taper
Number of subjects: 84
Study 1676753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, prednisone, and plasma exchanges (Group B)
Number of subjects: 71
Study 1676753 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and plasma exchanges (Group A)
Number of subjects: 71
Study 6338693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) 8 g/day
Number of subjects: 91
Study 6338693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) 16 g/day
Number of subjects: 91
Study 6338693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) 32 g/day
Number of subjects: 91
Study 6338693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 91
Study 6338693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE)
Number of subjects: 91
Study 31958518 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right orbitofrontal cortex (rOFC) for 20 minutes
Number of subjects: 92
Study 31958518 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 92
Study 30762895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag 3 mg once daily for ≤ 7 days before an invasive procedure
Number of subjects: 215
Study 30762895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 30762895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lusutrombopag
Number of subjects: 215
Study 28449229 — intervention group
Group type: EXPERIMENTAL
Intervention: More, larger and harder pieces of food
Number of subjects: 0
Study 28449229 — intervention group
Group type: COMPARATOR
Intervention: Less, smaller and softer pieces of food
Number of subjects: 0
Study 28449229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (more larger harder pieces and less smaller softer pieces)
Number of subjects: 0
Study 27141168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard splint
Number of subjects: 45
Study 27141168 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft splint
Number of subjects: 45
Study 27141168 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oral splint
Number of subjects: 45
Study 24241606 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme (EG, n=53)
Number of subjects: 108
Study 24241606 — intervention group
Group type: COMPARATOR
Intervention: Normal care (CG, n=55)
Number of subjects: 108
Study 21900844 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified derived equation for predicting maximal HR: 119 + 0.5 (resting HR) - 0.5 (age) - (0, if test was completed using a treadmill; 5, if using a stationary bike)
Number of subjects: 0
Study 21900844 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation 220 - age
Number of subjects: 0
Study 21034901 — intervention group
Group type: EXPERIMENTAL
Intervention: AFI+TH (autofluorescence imaging with a transparent hood)
Number of subjects: 561
Study 21034901 — intervention group
Group type: COMPARATOR
Intervention: WLI alone (white light imaging without a transparent hood)
Number of subjects: 561
Study 21034901 — intervention group
Group type: EXPERIMENTAL
Intervention: WLI+TH (white light imaging with a transparent hood)
Number of subjects: 561
Study 21034901 — intervention group
Group type: EXPERIMENTAL
Intervention: AFI alone (autofluorescence imaging without a transparent hood)
Number of subjects: 561
Study 17534958 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ER)
Number of subjects: 20
Study 15875066 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-9
Number of subjects: 6
Study 15875066 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-9R
Number of subjects: 6
Study 15875066 — intervention group
Group type: EXPERIMENTAL
Intervention: hCLCA1 (protein and mRNA)
Number of subjects: 6
Study 15875066 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucin production (periodic acid-Schiff staining)
Number of subjects: 6
Study 11956848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 196
Study 11956848 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin microemulsion (CyA)
Number of subjects: 196
Study 9708659 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/day
Number of subjects: 521
Study 9708659 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 521
Study 7543597 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of the AUA symptom index
Number of subjects: 124
Study 7543597 — intervention group
Group type: COMPARATOR
Intervention: Interviewer administration of the AUA symptom index
Number of subjects: 124
Study 2670034 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol (200 mgI/ml)
Number of subjects: 261
Study 2670034 — intervention group
Group type: COMPARATOR
Intervention: iohexol (240 mgI/ml)
Number of subjects: 261
Study 315162 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary arterial bypass surgery
Number of subjects: 102
Study 315162 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 102
Study 31924513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 4805
Study 31924513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4805
Study 31924513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab with taxane
Number of subjects: 4805
Study 31924513 — intervention group
Group type: COMPARATOR
Intervention: Placebo with taxane
Number of subjects: 4805
Study 30664453 — intervention group
Group type: EXPERIMENTAL
Intervention: NoteAid (active resource providing definitions for medical concepts)
Number of subjects: 0
Study 30664453 — intervention group
Group type: COMPARATOR
Intervention: MedlinePlus (passive self-service educational resource)
Number of subjects: 0
Study 30664453 — intervention group
Group type: COMPARATOR
Intervention: Baseline group (no resources provided)
Number of subjects: 0
Study 27755017 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (15 mg daily)
Number of subjects: 41
Study 27755017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25315667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra virgin olive oil (Med‐EVOO)
Number of subjects: 200